% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Salwender:288715,
author = {H. Salwender and N. Weinhold and A. Benner$^*$ and K.
Miah$^*$ and M. Merz and M. Haenel and C. Jehn and E. Mai
and E. Menis and I. Blau and C. Scheid and D. Hose and A.
Seckinger and S. Luntz and B. Besemer and M. Munder and P.
Brossart and B. Glass and H.-W. Lindemann and K. Weisel and
C. Hanoun and P. Schnitzler and S. Klemm and H. Goldschmidt
and M. Raab and A. Elmaagacli},
title = {{C}ytomegalovirus immunoglobulin serology prevalence in
patients with newly diagnosed multiple myeloma treated
within the {GMMG}-{MM}5 phase {III} trial.},
journal = {Hematology},
volume = {29},
number = {1},
issn = {1024-5332},
address = {Abingdon, Oxon},
publisher = {Taylor $\&$ Francis},
reportid = {DKFZ-2024-00434},
pages = {2320006},
year = {2024},
abstract = {The seroprevalence of antibodies against Cytomegalovirus
(CMV) is an established poor prognostic factor for patients
receiving an allogeneic stem cell transplantation. However,
the impact of CMV serology on outcome after autologous stem
cell transplantation remains unknown.Here, we analyzed the
CMV immunoglobulin (Ig) serology of 446 newly-diagnosed
multiple myeloma (MM) patients of the GMMG-MM5 phase III
trial with a median follow-up of 58 months.CMV IgG and IgM
positivity was seen in $51\%$ and $6\%$ of the patients,
respectively. In multivariate analysis CMV IgG and CMV IgM
serology show an age-depending effect for PFS. We identified
positive CMV IgG/positive CMV IgM serology as an
age-depending beneficial factor on PFS.Younger patients with
a positive CMV IgG/positive CMV IgM serology experienced a
favorable effect on PFS, whereas a positive CMV IgG/positive
CMV IgM serology at older age has a disadvantageous effect
on PFS.},
keywords = {Humans / Cytomegalovirus / Hematopoietic Stem Cell
Transplantation / Multiple Myeloma: diagnosis / Multiple
Myeloma: therapy / Prevalence / Seroepidemiologic Studies /
Transplantation, Autologous / Immunoglobulins, Intravenous /
Antibodies, Viral / Immunoglobulin G / Cytomegalovirus
Infections: epidemiology / Immunoglobulin M / CMV (Other) /
CMV IgM (Other) / CMV-Infection (Other) / GMMG-MM5 Phase III
Trial (Other) / age-depending effect (Other) / autologous
stem cell transplantation (Other) / maintenance therapy
(Other) / multiple myeloma (Other) /
cytomegalovirus-specific hyperimmune globulin (NLM
Chemicals) / Immunoglobulins, Intravenous (NLM Chemicals) /
Antibodies, Viral (NLM Chemicals) / Immunoglobulin G (NLM
Chemicals) / Immunoglobulin M (NLM Chemicals)},
cin = {C060},
ddc = {610},
cid = {I:(DE-He78)C060-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38407192},
doi = {10.1080/16078454.2024.2320006},
url = {https://inrepo02.dkfz.de/record/288715},
}